Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction

Naval Hospital, Athens

Status: Unknown

Conditions: Dry Eye; Meibomian Gland Dysfunction; Dry Eye Syndromes

Treatments: Procedure: laser light

Study type: Interventional

Funder types: Other

Identifiers

NCT04425551

6/19

Details and patient eligibility

About

The modern treatment of meibomian gland dysfunction(MGD) is based on anti-inflammatory drops or oral antibiotics for decreasing dry eye disease (DED) associated inflammation, warm compresses for liquefying the thicker meibum, and lid hygiene for reducing the bacterial overload. But, such treatments have shown limited effectiveness to a large proportion of patients with MGD, due to the multifactorial background of the disease. Thus, alternative approaches aiming at different aspects of the DED pathophysiology are needed.

Elimination of posterior lid-margin hyperemia with telangiectasia could be a treatment target for reducing the secretion of inflammatory mediators in the course of MGD. Using the mechanism of photocoagulation via selective thermolysis, laser light could contribute to the destruction of abnormal vessels at the posterior lid-margin and thus, the reduction of inflammation. Recently, sub-threshold (micropulse) laser photocoagulation was introduced in ophthalmology and offers significant clinical advantages compared to conventional continuous wave (CW) approach, preventing laser induced thermal damage and related treatment side effects.

This study investigates the effect of sub-threshold (micropulse) laser treatment for dry eye disease due to meibomian gland dysfunction combined with increased eyelid margin vascularity.

Enrollment: 15 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18-80 years
• chief complaint of more than one of dryness, foreign-body sensation, burning, and tearing for 3 months
• diagnosis of MGD with palpebral telangiectasia in both eyes

Exclusion criteria

• ocular structural abnormalities
• history of ocular trauma or surgery
• use of any treatment for DE or MGD, other than artificial tears, within the past month
• active allergy, infection, or inflammatory disease at the ocular surface unrelated to DE or MGD
• lacrimal drainage-system anomalies
• contact-lens wear
• use of any systemic anti-inflammatory medicine

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

15 participants in 2 patient groups

Treated

Active Comparator group

Description:

The lower eyelid margin of the clinically worse eye was selected for treatment. A slit lamp based 532 nm optically pumped dual diode solid state SP-Mode (subthreshold) laser system was used. After cleaning eyelids with a cosmetic face wash, a drop of proparacaine hydrochloride 0.5% was then administered onto the conjunctival sac. No eye or cornea shield was used, since laser light was directly aimed at telangiectasias. The treatment parameters were set with 50 μm spot size and 200 ms duration with 30% duty cycle. The power ranged from 1500 to 1700 mW with monospot micropulse model and a just visible destruction of the telangiectatic vessels served as the threshold burn. After the procedure, the patient received corticosteroid ointment for 5 days on both eyes and was advised to continue applying her pre-treatment medication on both eyes.

Treatment:

Procedure: laser light

Untreated

No Intervention group

Description:

The lateral eye was observed as control.